A Phase 4 interventional study of Sandimmune and Artelose in Endothelial Graft Rejection, sponsored by Shahid Beheshti University of Medical Sciences. Completed at 2 sites in Iran, Islamic Republic of. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2009-12-09.
Sponsored by Shahid Beheshti University of Medical Sciences · Phase 4 and Interventional
The use of topical Cyclosporine A early after an episode of endothelial graft rejection after penetrating keratoplasty and continuing its administration for 6 months can reduce the course of that episode and recurrence of the rejection.
Shahid Beheshti University of Medical Sciences is the lead sponsor of 221 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Sandimmune
Drug: Artelose
The rate of rejection after drop sessation
Time frame: 3 years
This study is completed, as verified in Apr 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shahid Beheshti University of Medical Sciences